“In parallel with commencement of the trial, the Company is pleased to be enhancing its patient advocacy interactions with Dr Gil Price’s participation in the upcoming Parent Project Muscular Dystrophy (PPMD) 9th annual conference (29 June to 1 July 2023; https://web.cvent.com/event/f695ea28-c338-4307-bbd3-c5b27a9fae3e/summary) where he will present on ATL1102 and the Phase IIb study.”
Someone was asking for Gil Price to attend the PPMD conference..this am
Wow! Management must be reading HC.
Now : GP has something to deliver $$. . Hope PPMD will give Anp the attention they have given Sarepta.
Up Up and away !!
Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK, page-11
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.5¢ | $38.88K | 514.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 39300 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 26315 | 1 |
View Market Depth
| Last trade - 15.19pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
-0.001 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.8¢ | 7.5¢ | 112689 | ||
| Last updated 15.50pm 21/05/2024 ? | |||||
| PER (ASX) Chart |